These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16910584)

  • 21. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
    Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
    Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
    J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum PSA levels at 6 month after surgery, TURP or Doxazosin therapy for BPH.
    Dutkiewicz S; Stepień K
    Mater Med Pol; 1996; 28(2):69-70. PubMed ID: 9088130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of acute urinary retention on serum prostate specific antigen concentration].
    Hua LX; Wu HF; Sui YG; Cheng SG; Xu ZQ
    Zhonghua Nan Ke Xue; 2002; 8(2):134-5. PubMed ID: 12479031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
    Alexander BM; Chen MH; Carroll P; D'Amico AV
    Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA velocity in conservatively managed BPH: can it predict the need for BPH-related invasive therapy?
    Mochtar CA; Kiemeney LA; Laguna MP; Debruyne FM; de la Rosette JJ
    Prostate; 2006 Sep; 66(13):1407-12. PubMed ID: 16741919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy.
    Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
    Urology; 2007 Jan; 69(1):129-33. PubMed ID: 17270634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The use of serpens for treating patients with benign prostatic hyperplasia].
    Mazo EB; Chekhonin VP; Riabukhin IA; Grigor'ev ME
    Ter Arkh; 1996; 68(10):47-9. PubMed ID: 9026943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy.
    Kurita Y; Masuda H; Suzuki K; Fujita K; Kawabe K
    Br J Urol; 1997 Jul; 80(1):78-83. PubMed ID: 9240185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary PSA in monitoring of patients with prostate cancer.
    Pejcić T; Dimitrijević V; Hadzi-Djokić J
    Acta Chir Iugosl; 2012; 59(1):57-60. PubMed ID: 22924305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level.
    van Renterghem K; Van Koeveringe G; Achten R; Van Kerrebroeck P
    Eur Urol; 2007 Sep; 52(3):819-26. PubMed ID: 17418482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.